Skip to content

Study · Not a test of the peptide alone · 2013

5 results

Amelioration of neurodegenerative diseases by cell death-induced cytoplasmic delivery of humanin.

Park TY, Kim SH, Shin YC, Lee NH, Lee RK, Shim JH, Glimcher LH, Mook-Jung I, Cheong E, Kim WK, Honda F, Morio T, Lim JS, Lee SK

Journal of controlled release : official journal of the Controlled Release Society5 Jan 2013Cited by 17 (Europe PMC)

PMID23298615 (opens in a new tab)DOI10.1016/j.jconrel.2012.12.022 (opens in a new tab)PepBankPUB-23298615
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Humanin.

  1. 01AnimalNot a test of Humanin aloneAnimal study (in vivo)Efficacy outcome

    In animal models of Alzheimer's disease and stroke, tHN-C3 prevented neuronal cell death.

    In plain wordsIn mice and rats, a modified humanin construct reduced brain cell death in models of Alzheimer's disease and stroke.

    Peptide
    Humanin
    Outcome
    DecreaseNeuronal cell death in AD and stroke models
    Study

    mice, ratsn: not reported in source

    Amyloid beta-induced AD model, Tg2576 mice, rat MCAO stroke model
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    In animal models of AD induced by amyloid beta, in Tg2576 mice, and in the rat middle cerebral artery occlusion model of stroke, tHN-C3 effectively prevented neuronal cell death, inflammatory cell infiltration into the brain, and improved cognitive memory.

    In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.

  2. 02AnimalNot a test of Humanin aloneAnimal study (in vivo)Efficacy outcome

    In animal models of Alzheimer's disease and stroke, tHN-C3 prevented inflammatory cell infiltration into the brain.

    In plain wordsIn mice and rats, a modified humanin construct reduced inflammatory cells entering the brain in models of Alzheimer's disease and stroke.

    Peptide
    Humanin
    Outcome
    DecreaseInflammatory cell infiltration into the brain
    Study

    mice, ratsn: not reported in source

    Amyloid beta-induced AD model, Tg2576 mice, rat MCAO stroke model
    Outcome group
    Inflammation markers · Nervous system and cognition

    Source sentences

    Summary
    In animal models of AD induced by amyloid beta, in Tg2576 mice, and in the rat middle cerebral artery occlusion model of stroke, tHN-C3 effectively prevented neuronal cell death, inflammatory cell infiltration into the brain, and improved cognitive memory.

    In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.

  3. 03AnimalNot a test of Humanin aloneAnimal study (in vivo)Efficacy outcome

    In animal models of Alzheimer's disease and stroke, tHN-C3 improved cognitive memory.

    In plain wordsIn mice and rats, a modified humanin construct improved memory in models of Alzheimer's disease and stroke.

    Peptide
    Humanin
    Outcome
    IncreaseCognitive memory
    Study

    mice, ratsn: not reported in source

    Amyloid beta-induced AD model, Tg2576 mice, rat MCAO stroke model
    Outcome group
    Cognition and memory · Nervous system and cognition

    Source sentences

    Summary
    In animal models of AD induced by amyloid beta, in Tg2576 mice, and in the rat middle cerebral artery occlusion model of stroke, tHN-C3 effectively prevented neuronal cell death, inflammatory cell infiltration into the brain, and improved cognitive memory.

    In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.

  4. 04AnimalNot a test of Humanin aloneAnimal study (in vivo)Efficacy outcome

    In animal models, the therapeutic effectiveness of tHN-C3 was comparable to that of Aricept.

    In plain wordsIn animals, a modified humanin construct worked about as well as Aricept, a drug approved for Alzheimer's disease.

    Peptide
    Humanin
    Outcome
    No significant changeEffectiveness compared with Aricept
    Study

    mice, ratsn: not reported in source

    Amyloid beta-induced AD model, Tg2576 mice, rat MCAO stroke model
    Comparator
    Aricept
    Outcome group
    Cognition and memory · Nervous system and cognition

    Source sentences

    Summary
    The therapeutic effectiveness of tHN-C3 was comparable to that of Aricept, a clinically approved drug for AD treatment.

    In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.

  5. 05LabNot a test of Humanin aloneIn vitro (cells)Efficacy outcome

    In neuronal cells, the humanin construct tHN-C3 prevented cell death induced by H2O2 or soluble Aβ42.

    In plain wordsIn neuronal cells, a modified humanin construct stopped cell death caused by H2O2 or Aβ42.

    Peptide
    Humanin
    Outcome
    DecreaseNeuronal cell death induced by H2O2 or soluble Aβ42
    Study

    n: not reported in source

    Neuronal cells
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    The tHN-C3 prevented neuronal cell death induced by H2O2, or soluble Aβ42, via Bax binding.

    In this study, Humanin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Humanin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.